Cardiovascular effects of cyclooxygenase-2 inhibitors

Current Opinion in Gastroenterology

Volumn 23, Issue 6, 2007, Pages 617-624

  Brophy, James M ^a,b  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Adverse effect; Cyclooxygenase inhibitor; Myocardial infarction; Nonsteroidal antiinflammatory agent; Pharmacoepidemiology

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; VALDECOXIB;

BRAIN ISCHEMIA; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG FATALITY; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; LUNG EDEMA; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SINGLE DRUG DOSE; STOMACH DISEASE; STROKE; THROMBOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; CYCLOOXYGENASE 2 INHIBITORS; HEART; HUMANS; LACTONES; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SULFONAMIDES; SULFONES;

EID: 34848869089     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3282f026a7     Document Type: Review

References (46)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343:1520-1528.
2. Food and Drug Administration. Joint meeting with the drug safety and risk management advisory committee. Rockville: Food and Drug Administration, 16-18 February, 2005. http://www.fda.gov/ohrms/dockets/ac/cder05.html#Arthritis. [accessed 30 May 2007] Detailed presentation by sponsors, FDA and academics that summarized the 2005 totality of the evidence and discussed the implications.
3. Psaty BM, Burke SP. Protecting the Health of the Public - Institute of Medicine Recommendations on Drug Safety. N Engl J Med 2006; 355:1753-1755.
4. Hennessy S, Strom BL. PDUFA reauthorisation - drug safety's golden moment of opportunity? N Engl J Med 2007; 356:1703-1704.
5. Avorn J. Paying for drug approvals - who's using whom? N Engl J Med 2007; 356:1697-1700.
6. Food and Drug Administration. Meeting of a Public Advisory Committee of the Food and Drug Administration. Rockville: Food and Drug Administration, 12 April 2007. 2007 http://www.fda.gov/ohrms/dockets/ac/cder07.htm#ArthritisDrugs. [accessed 30 May 2007]
7. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclo-oxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332:1302-1308. Detailed meta-analysis of all available RCTs providing risks estimates for both selective and nonselective NSAIDs.
8. Psaty BM, Weiss NS. NSAID trials and the choice of comparators - questions of public health importance. N Engl J Med 2007; 356:328-330.
9. Song F, Altman DG, Glenny AM, Deeks JJ. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. BMJ 2003; 326:472.
10. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296:1633-1644. Detailed meta-analysis of available observational studies providing risks estimates for both selective and nonselective NSAIDs.
11. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001; 345:1809-1817.
12. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105:31S-38S.
13. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364:2021-2029.
14. Food and Drug Administration Advisory Committee. Cardiovascular safety review of rofeocoxib. Rockville: Food and Drug Administration, 2001. http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b2_06_cardio.pdf. [accessed 30 August 2006]
15. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286:954-959.
16. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-1102.
17. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003; 125:1481-1492.
18. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005; 352:1081-1091.
19. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352:1071-1080.
20. ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006; 1:e33. RCT suggesting no cardiovascular risk for celecoxib compared to naproxen.
21. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-1255.
22. Topol EJ, Falk GW. A coxib a day won't keep the doctor away. Lancet 2004; 364:639-640.
23. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006; 368:1771-1781. Largest NSAID cardiovascular trial ever performed.
24. Curtis SP, Ko AT, Bolognese JA, et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective inhibitor etoricoxib. Curr Med Res Opin 2006; 22:2365-2374.
25. Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983; 2:267-271.
26. Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142:481-489.
27. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006; 27:1657-1663.
28. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective nonsteroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365:475-481.
29. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142:157-164.
30. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330:1366.
31. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165:978-984.
32. Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109:2068-2073.
33. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006; 113:1950-1957.
34. Shaya FT, Blume SW, Blanchette CM, et al. Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med 2005; 165:181-186.
35. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003; 163:481-486.
36. Brophy JM, Lévesque L, Zhang B. The coronary risks with selective cyclooxygenase-2 inhibitors in patients with prior myocardial infarction. Heart 2007; 93:189-194.
37. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113:2906-2913.
38. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [correction]. N Engl J Med 2006; 355:221.
39. Levesque LE, Brophy JM, Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 2006; 174:1563-1569.
40. Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-h blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165:161-168.
41. Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8:85-95.
42. Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90:959-963.
43. Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165:490-496.
44. Mamdani M, Juurlink DN, Lee DS, et al. Cyclo-oxygenase-2 inhibitors versus nonselective nonsteroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004; 363:1751-1756.
45. Hudson M, Richard H, Pilote L. Differences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or nonsteroidal anti-inflammatory drugs: population based study. BMJ 2005; 330:1370.
46. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events meta-analysis of randomized trials. JAMA 2006; 296:1619-1632.